213 related articles for article (PubMed ID: 26345573)
1. [Successful treatment of venous thromboembolism with a Factor Xa inhibitor, edoxaban, in patients with lenalidomide-treated multiple myeloma].
Kawaguchi M; Uchimura N; Okuda Y; Konuma S; Nehashi Y
Rinsho Ketsueki; 2015 Aug; 56(8):1096-9. PubMed ID: 26345573
[TBL] [Abstract][Full Text] [Related]
2. [Successful management of venous thromboembolism with apixaban in a multiple myeloma patient on lenalidomide therapy].
Oka S; Takeuchi S; Shiragami H; Hamahata K; Nohgawa M
Rinsho Ketsueki; 2017; 58(1):37-41. PubMed ID: 28190864
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study.
Preblick R; Kwong WJ; White RH; Goldhaber SZ
Hosp Pract (1995); 2015; 43(5):249-57. PubMed ID: 26549305
[TBL] [Abstract][Full Text] [Related]
4. Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
Brekelmans M; Middeldorp S; Coppens M
Expert Rev Hematol; 2015 Dec; 8(6):707-25. PubMed ID: 26560872
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of edoxaban, an oral direct factor Xa inhibitor, on venous thromboembolism between patients with and without cancer.
Ikeda S; Koga S; Yamagata Y; Eguchi M; Sato D; Muroya T; Yonekura T; Tsuneto A; Yoshimuta T; Koide Y; Kawano H; Maemura K
J Cardiol; 2018 Aug; 72(2):120-127. PubMed ID: 29661489
[TBL] [Abstract][Full Text] [Related]
6. Edoxaban: A Novel Factor Xa Inhibitor for the Management of Non-valvular Atrial Fibrillation and Venous Thromboembolism.
Kubli KA; Snead JA; Cheng-Lai A
Cardiol Rev; 2016; 24(4):205-10. PubMed ID: 26991962
[TBL] [Abstract][Full Text] [Related]
7. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial.
Verhamme P; Wells PS; Segers A; Ageno W; Brekelmans MP; Cohen AT; Meyer G; Grosso MA; Raskob G; Weitz JI; Zhang G; Buller H
Thromb Haemost; 2016 Sep; 116(4):747-53. PubMed ID: 27440518
[TBL] [Abstract][Full Text] [Related]
8. The use of factor Xa inhibitors following opening-wedge high tibial osteotomy for venous thromboembolism prophylaxis.
Kobayashi H; Akamatsu Y; Kumagai K; Kusayama Y; Ishigatsubo R; Mitsuhashi S; Kobayashi A; Aratake M; Saito T
Knee Surg Sports Traumatol Arthrosc; 2017 Sep; 25(9):2929-2935. PubMed ID: 27000391
[TBL] [Abstract][Full Text] [Related]
9. [Hokusai-VTE: edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism].
Sprynger M
Rev Med Liege; 2013 Oct; 68(10):548-51. PubMed ID: 24298731
[TBL] [Abstract][Full Text] [Related]
10. Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice.
Barrios V; Escobar C
Future Cardiol; 2016 Jul; 12(4):419-33. PubMed ID: 27121025
[TBL] [Abstract][Full Text] [Related]
11. Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?
Gibson CM; Finks SW
Am J Med; 2017 Aug; 130(8):900-906. PubMed ID: 28390791
[TBL] [Abstract][Full Text] [Related]
12. Edoxaban is effective in reducing the incidence of asymptomatic phlebographic events following closed-wedge high tibial osteotomy.
Kobayashi H; Akamatsu Y; Kumagai K; Kusayama Y; Okuyama H; Hirotomi K; Shinohara K; Saito T
Orthop Traumatol Surg Res; 2017 Dec; 103(8):1193-1196. PubMed ID: 28928048
[TBL] [Abstract][Full Text] [Related]
13. Edoxaban, a Novel Oral Factor Xa Inhibitor.
Minor C; Tellor KB; Armbruster AL
Ann Pharmacother; 2015 Jul; 49(7):843-50. PubMed ID: 25855704
[TBL] [Abstract][Full Text] [Related]
14. Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide.
Isoda A; Sato N; Miyazawa Y; Matsumoto Y; Koumoto M; Ookawa M; Sawamura M; Matsumoto M
Int J Hematol; 2015 Sep; 102(3):271-7. PubMed ID: 26177588
[TBL] [Abstract][Full Text] [Related]
15. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
Palumbo A; Rajkumar SV; Dimopoulos MA; Richardson PG; San Miguel J; Barlogie B; Harousseau J; Zonder JA; Cavo M; Zangari M; Attal M; Belch A; Knop S; Joshua D; Sezer O; Ludwig H; Vesole D; Bladé J; Kyle R; Westin J; Weber D; Bringhen S; Niesvizky R; Waage A; von Lilienfeld-Toal M; Lonial S; Morgan GJ; Orlowski RZ; Shimizu K; Anderson KC; Boccadoro M; Durie BG; Sonneveld P; Hussein MA;
Leukemia; 2008 Feb; 22(2):414-23. PubMed ID: 18094721
[TBL] [Abstract][Full Text] [Related]
16. Edoxaban tosylate.
Am J Cardiovasc Drugs; 2011; 11(2):129-35. PubMed ID: 21446778
[TBL] [Abstract][Full Text] [Related]
17. Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review.
Al-Ani F; Bermejo JM; Mateos MV; Louzada M
Thromb Res; 2016 May; 141():84-90. PubMed ID: 26986753
[TBL] [Abstract][Full Text] [Related]
18. Edoxaban (LIXIANA
Bottino R; Carbone A; Liccardo B; D'Andrea A; Rago A; Papa AA; Spaccarotella C; Golino P; Nigro G; Russo V
Future Cardiol; 2021 Aug; 17(5):779-791. PubMed ID: 33231106
[TBL] [Abstract][Full Text] [Related]
19. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial.
Vanassche T; Verhamme P; Wells PS; Segers A; Ageno W; Brekelmans MPA; Chen CZ; Cohen AT; Grosso MA; Medina AP; Mercuri MF; Winters SM; Zhang G; Weitz JI; Raskob GE; Büller HR
Thromb Res; 2018 Feb; 162():7-14. PubMed ID: 29248859
[TBL] [Abstract][Full Text] [Related]
20. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study.
van Es N; Di Nisio M; Bleker SM; Segers A; Mercuri MF; Schwocho L; Kakkar A; Weitz JI; Beyer-Westendorf J; Boda Z; Carrier M; Chlumsky J; Décousus H; Garcia D; Gibbs H; Kamphuisen PW; Monreal M; Ockelford P; Pabinger I; Verhamme P; Grosso MA; Büller HR; Raskob GE
Thromb Haemost; 2015 Nov; 114(6):1268-76. PubMed ID: 26271200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
